Literature DB >> 18239083

Telomere maintenance and human bone marrow failure.

Rodrigo T Calado1, Neal S Young.   

Abstract

Acquired and congenital aplastic anemias recently have been linked molecularly and pathophysiologically by abnormal telomere maintenance. Telomeres are repeated nucleotide sequences that cap the ends of chromosomes and protect them from damage. Telomeres are eroded with cell division, but in hematopoietic stem cells, maintenance of their length is mediated by telomerase. Accelerated telomere shortening is virtually universal in dyskeratosis congenita, caused by mutations in genes encoding components of telomerase or telomere-binding protein (TERT, TERC, DKC1, NOP10, or TINF2). About one-third of patients with acquired aplastic anemia also have short telomeres, which in some cases associate with TERT or TERC mutations. These mutations cause low telomerase activity, accelerated telomere shortening, and diminished proliferative capacity of hematopoietic progenitors. As in other genetic diseases, additional environmental, genetic, and epigenetic modifiers must contribute to telomere erosion and ultimately to disease phenotype. Short telomeres also may cause genomic instability and malignant progression in these marrow failure syndromes. Identification of short telomeres has potential clinical implications: it may be useful in dyskeratosis congenita diagnosis, in suggesting mutations in patients with acquired aplastic anemia, and for selection of suitable hematopoietic stem cell family donors for transplantation in telomerase-deficient patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239083      PMCID: PMC2343587          DOI: 10.1182/blood-2007-08-019729

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  94 in total

1.  A telomerase component is defective in the human disease dyskeratosis congenita.

Authors:  J R Mitchell; E Wood; K Collins
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

2.  Telomere length changes in patients with aplastic anaemia.

Authors:  J J Lee; H Kook; I J Chung; J A Na; M R Park; T J Hwang; J Y Kwak; S K Sohn; H J Kim
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

3.  Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery.

Authors:  K L Rudolph; S Chang; M Millard; N Schreiber-Agus; R A DePinho
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

Review 4.  Dyskeratosis congenita in all its forms.

Authors:  I Dokal
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

Review 5.  Mice without telomerase: what can they teach us about human cancer?

Authors:  S E Artandi; R A DePinho
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

Review 6.  Studies of the molecular mechanisms in the regulation of telomerase activity.

Authors:  J P Liu
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

7.  Telomere length in leukocyte subpopulations of patients with aplastic anemia.

Authors:  T H Brümmendorf; J P Maciejewski; J Mak; N S Young; P M Lansdorp
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

Review 8.  Hormones and growth factors regulate telomerase activity in ageing and cancer.

Authors:  Sharyn Bayne; Jun-Ping Liu
Journal:  Mol Cell Endocrinol       Date:  2005-08-30       Impact factor: 4.102

9.  Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita.

Authors:  T J Vulliamy; S W Knight; P J Mason; I Dokal
Journal:  Blood Cells Mol Dis       Date:  2001 Mar-Apr       Impact factor: 3.039

10.  Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10.

Authors:  V Pogacić; F Dragon; W Filipowicz
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

View more
  80 in total

1.  Telomere length in myelodysplastic syndromes.

Authors:  Dana E Rollison; P K Epling-Burnette; Jong Y Park; Ji-Hyun Lee; Hyun Park; Kristen Jonathan; Ashley L Cole; Jeffrey S Painter; Mayenha Guerrier; Johana Meléndez-Santiago; William Fulp; Rami Komrokji; Jeffrey Lancet; Alan F List
Journal:  Leuk Lymphoma       Date:  2011-06-03

Review 2.  Assessing cell and organ senescence biomarkers.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

3.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

Review 4.  Adrenocortical stem and progenitor cells: unifying model of two proposed origins.

Authors:  Michelle A Wood; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2010-11-20       Impact factor: 4.102

5.  Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.

Authors:  Rodrigo T Calado; Joshua A Regal; Mark Hills; William T Yewdell; Leandro F Dalmazzo; Marco A Zago; Peter M Lansdorp; Donna Hogge; Stephen J Chanock; Elihu H Estey; Roberto P Falcão; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-15       Impact factor: 11.205

6.  Telomere length is inherited with resetting of the telomere set-point.

Authors:  Y Jeffrey Chiang; Rodrigo T Calado; Karen S Hathcock; Peter M Lansdorp; Neal S Young; Richard J Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 7.  Cancer stem cells: relevance to SCT.

Authors:  T Lin; R J Jones; W Matsui
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

8.  p16(INK4a) protects against dysfunctional telomere-induced ATR-dependent DNA damage responses.

Authors:  Yang Wang; Norman Sharpless; Sandy Chang
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 9.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

10.  Solution structure and dynamics of the wild-type pseudoknot of human telomerase RNA.

Authors:  Nak-Kyoon Kim; Qi Zhang; Jing Zhou; Carla A Theimer; Robert D Peterson; Juli Feigon
Journal:  J Mol Biol       Date:  2008-10-11       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.